Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea

Nordic Pharma logo

Nordic Pharma

Status

Completed

Conditions

Medical Termination of Pregnancy

Study type

Observational

Funder types

Industry

Identifiers

NCT02614781
RYMMA

Details and patient eligibility

About

This study is a non-interventional prospective, multicenter, longitudinal study conducted in France, among a representative sample of public and/or private birth control centers. The aim of the study is to assess, in real-life settings, the success rate of the protocol Mifegyne / prostaglandin analogue in patients asking for medical abortion either prior or beyond 7 weeks of amenorrhea.

Enrollment

892 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Adult women (≥ 18 years old) with confirmed intra-uterine pregnancy consulting for medical termination of pregnancy * Patients for whom the physician decides to use a Mifegyne 600 mg and prostaglandin analogue combination for medical abortion * Patients agreeing to participate in the study after having been informed orally by the physician and given the information sheet * Informed patients accepting the computer processing of their medical data and their right of access and correction

Exclusion criteria

* Patients with known hypersensitivity to mifepristone * Patients with known hypersensitivity to prostaglandin analogues (misoprostol or gemeprost). * Patients with severe and progressive disease * Patients with ectopic pregnancy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems